Eni...Dogs and Horses, for pussy's lovers only - Cap. 3
- Creatore Discussione Comoduca
- Data di Inizio
Covidiotissimo
Forumer attivo
Ma se il vax (che vax non è) non ha il virus i vaxxati di cosa si ammalano?
Covidiotissimo
Forumer attivo
Poi che faranno, lo renderanno obbligatorio perché tradizionale?!?
Comoduca
co-founder
0,0195 contro 0,0830 si ok è un po’ meno ……..425,6%sei sicuro? avevo letto molto meno!
snapo
the greater the truth, the greater the libel
lo statistico sanitario cerca e trova che
uttar pradesh ha usato massivamente INVERMECTINA in profilassi da MAGGIO
indonesia ha usato massivamente INVERMECTINA in profilasi da LUGLIO
giappone nn ha mai fatto profilassi invermectina ufficialmente ma...ai primi di agosto e quando la curva dei contagi saliva rapidamente...il presidente dell'ordine dei medici giapponese ebbe a dire "ABBIAMO RISCONTRATO CHE NEI PAESI AFRICANI DOVE VIENE SOMMINISTRATA IN PROFILASSI INVERMECTINA PER CURARE LA FILIAROSI IL TASSO DI CONTAGIO COVID E' 1/15 RISPETTO AGLI ALTRI PAESI DEL CONTINENTE...NN SAPPIAMO SE FUNZIONI MA IN EMERGENZA IL DOVERE DI UN MEDICO E' DI FARE TUTTO QUELLO CHE PUO' SERVIRE PER SALVARE VITE"
nn sappiamo cosa sia accaduto in quei mesi ma da medico se io avessi sentito dire quelle parole dal presidente dell'ordine lo avrei seguito e avrei provato(sempre meglio della morte certa col propofol di bergamo intubati no?)
veniamo a taiwan
ho trovato una dichiarazione ufficiale in cui "nn si raccomanda" l'uso dell'ivermectina nel mentre dati e studi ovunque dimostravano che in profilassi funzionasse di brutto...
quello che mi ha colpito sono le parole e il tono a dimostrazione che nel paese la stesso usando di brutto...
articolo
"Following an expert meeting, we do not recommend regular use of ivermectin in treating COVID-19 due to lack of enough evidence," Chang Shan-chwen (張上淳), convener of the Central Epidemic Command Center's (CECC) expert advisory panel, told a daily press briefing.
According to a recent report in the American Journal of Therapeutics, meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.
"Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin," the report said.
Although initial findings showed that ivermectin seemed effective in the prevention and treatment of COVID-19, Chang, however, said no meaningful evidence has been discovered to fully verify that it helps bring down patients' mortality or intubation rate.
Neither is there evidence to prove that it speeds up the elimination of the coronavirus or shortens the length of a patient's hospital stay, because of the limited number of cases studied, he said.
Ivermectin, a medication used to treat many types of parasite infestations, was first used in 1988 to treat river blindness, a disease caused by infection from the parasitic worm Onchocerca volvulus. Since 2012, several studies showed antiviral effects of ivermectin on RNA viruses such as flu, dengue fever and acquired immunodeficiency syndrome (AIDS).
Therefore, demand for approval of the drug is growing across the world, with some countries recommending ivermectin as a cure for COVID-19 patients -- despite leading health authorities consistently warning against its use.
As neither the World Health Organization nor the European Union or the United States have included ivermectin in their guidelines for COVID-19 treatment, the CECC decided not to recommend a regular use of the drug for such a purpose, Chang said.
He warned COVID-19 patients against buying the drug over the counter to treat the disease due to potential side effects caused by inappropriate use.
focustaiwan.tw
IN SINTESI
270.000.000 ABITANTI DELL'INDONESIA HANNO FATTO PROFILASSI CON INVERMECTINA
240.000.000 ABITANTI DEL UTTAR PRADESH HANNO FATTO PROFILASSI CON INVERMECTINA
120.000.000 ABITANTI GIAPPONE HANNO ASCOLTATO IL PRES ORD MEDICI DIRE CHE SE SERVE SI PROVA TUTTO...IN PARTICOLARE CIO' CHE ALTROVE DIMOSTRA FUNZIONARE
25.000.000 TAIWANESI SONO STATI NN RACCOMANDATI A USARE INVERMECTINA NEL MENTRE I CITTADINI LA COMPRAVANO A MANI BASSE
SONO 2 INDIZI PIENI
1 INDIZIO QUASI PIENO
1 UNA CONSIDERAZIONE + CHE LOGICA
NN SARA' MERITO DELL'INVERMECTINA?
ALLORA DI COSA...DEI MONSONI?
IL GIORNO CHE ACCENDERETE IL CERVELLO TUTTA BIG PHARMA FALLIRA'...QUEL GIORNO WS CADRA' ROVINOSAMENTE COME FECE IL NASDAQ NEL 2001-2002
SONO SOLO SOLDI...LE VITE NN CONTANO
buona domenica
uttar pradesh ha usato massivamente INVERMECTINA in profilassi da MAGGIO
indonesia ha usato massivamente INVERMECTINA in profilasi da LUGLIO
giappone nn ha mai fatto profilassi invermectina ufficialmente ma...ai primi di agosto e quando la curva dei contagi saliva rapidamente...il presidente dell'ordine dei medici giapponese ebbe a dire "ABBIAMO RISCONTRATO CHE NEI PAESI AFRICANI DOVE VIENE SOMMINISTRATA IN PROFILASSI INVERMECTINA PER CURARE LA FILIAROSI IL TASSO DI CONTAGIO COVID E' 1/15 RISPETTO AGLI ALTRI PAESI DEL CONTINENTE...NN SAPPIAMO SE FUNZIONI MA IN EMERGENZA IL DOVERE DI UN MEDICO E' DI FARE TUTTO QUELLO CHE PUO' SERVIRE PER SALVARE VITE"
nn sappiamo cosa sia accaduto in quei mesi ma da medico se io avessi sentito dire quelle parole dal presidente dell'ordine lo avrei seguito e avrei provato(sempre meglio della morte certa col propofol di bergamo intubati no?)
veniamo a taiwan
ho trovato una dichiarazione ufficiale in cui "nn si raccomanda" l'uso dell'ivermectina nel mentre dati e studi ovunque dimostravano che in profilassi funzionasse di brutto...
quello che mi ha colpito sono le parole e il tono a dimostrazione che nel paese la stesso usando di brutto...
articolo
"Following an expert meeting, we do not recommend regular use of ivermectin in treating COVID-19 due to lack of enough evidence," Chang Shan-chwen (張上淳), convener of the Central Epidemic Command Center's (CECC) expert advisory panel, told a daily press briefing.
According to a recent report in the American Journal of Therapeutics, meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.
"Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin," the report said.
Although initial findings showed that ivermectin seemed effective in the prevention and treatment of COVID-19, Chang, however, said no meaningful evidence has been discovered to fully verify that it helps bring down patients' mortality or intubation rate.
Neither is there evidence to prove that it speeds up the elimination of the coronavirus or shortens the length of a patient's hospital stay, because of the limited number of cases studied, he said.
Ivermectin, a medication used to treat many types of parasite infestations, was first used in 1988 to treat river blindness, a disease caused by infection from the parasitic worm Onchocerca volvulus. Since 2012, several studies showed antiviral effects of ivermectin on RNA viruses such as flu, dengue fever and acquired immunodeficiency syndrome (AIDS).
Therefore, demand for approval of the drug is growing across the world, with some countries recommending ivermectin as a cure for COVID-19 patients -- despite leading health authorities consistently warning against its use.
As neither the World Health Organization nor the European Union or the United States have included ivermectin in their guidelines for COVID-19 treatment, the CECC decided not to recommend a regular use of the drug for such a purpose, Chang said.
He warned COVID-19 patients against buying the drug over the counter to treat the disease due to potential side effects caused by inappropriate use.
Taiwan rules out regular use of antiparasitic drug to treat COVID - Focus Taiwan
As the common antiparasitic ivermectin is being touted as a cure for COVID-19 in many parts of the world, Taiwan's experts on Monday warned against regular use of the drug in COVID-19 treatment, citing a lack of solid evidence.
IN SINTESI
270.000.000 ABITANTI DELL'INDONESIA HANNO FATTO PROFILASSI CON INVERMECTINA
240.000.000 ABITANTI DEL UTTAR PRADESH HANNO FATTO PROFILASSI CON INVERMECTINA
120.000.000 ABITANTI GIAPPONE HANNO ASCOLTATO IL PRES ORD MEDICI DIRE CHE SE SERVE SI PROVA TUTTO...IN PARTICOLARE CIO' CHE ALTROVE DIMOSTRA FUNZIONARE
25.000.000 TAIWANESI SONO STATI NN RACCOMANDATI A USARE INVERMECTINA NEL MENTRE I CITTADINI LA COMPRAVANO A MANI BASSE
SONO 2 INDIZI PIENI
1 INDIZIO QUASI PIENO
1 UNA CONSIDERAZIONE + CHE LOGICA
NN SARA' MERITO DELL'INVERMECTINA?
ALLORA DI COSA...DEI MONSONI?
IL GIORNO CHE ACCENDERETE IL CERVELLO TUTTA BIG PHARMA FALLIRA'...QUEL GIORNO WS CADRA' ROVINOSAMENTE COME FECE IL NASDAQ NEL 2001-2002
SONO SOLO SOLDI...LE VITE NN CONTANO
buona domenica
snapo
the greater the truth, the greater the libel
snapo
the greater the truth, the greater the libel
snapo
the greater the truth, the greater the libel
NOT ONLY COVID
BUT
THE BANKRUPTCY OF BIG PHARMA
Ivermectin, 'wonder drug' from Japan: the human use perspective
New horizons
Ivermectin has continually proved to be astonishingly safe for human use. Indeed, it is such a safe drug, with minimal side effects, that it can be administered by non-medical staff and even illiterate individuals in remote rural communities, provided that they have had some very basic, appropriate training. This fact has helped contribute to the unsurpassed beneficial impact that the drug has had on human health and welfare around the globe, especially with regard to the campaign to fight Onchocerciasis.57)
Today, ivermectin is being increasingly used worldwide to combat other diseases in humans, such as Strongyloidiasis (which infects some 35 million each year), scabies (which causes 300 million cases annually), Pediculosis, Gnathostomiasis and Myiasis—and new and promising properties and uses for ivermectin and other avermectin derivatives are continuing to be found.58) These include activity against another neglected tropical disease, Leishmaniasis.59,60) Of perhaps even greater significance is the evidence that the use of ivermectin has both direct and indirect beneficial impact on improving community health. Studies of long-term treatment with ivermectin to control Onchocerciasis have shown that use of the drug is additionally associated with significant reduction in the prevalence of infection with any soil-transmitted helminth parasites (including Ascaris, Trichuris and hookworm), most or all of which are deemed to be major causes of the morbidity arising from poor childhood nutrition and growth.61) It is also known that the prevalence of head lice is markedly reduced in children taking ivermectin tablets62) and that scabies is markedly reduced in populations taking the drug regularly.63) Above all, ivermectin has proved to be a medicine of choice for the world’s rural poor. In many underprivileged communities throughout the tropics, intestinal worms and parasitic skin diseases are extremely common and associated with significant morbidity. They usually co-exist, with many individuals infected with both ecto- and endoparasites.64,65) Mass treatment of poly-parasitized populations is deemed to be the best means of control and ivermectin is the ideal drug for such interventions. A recent study in Brazil, using locally produced ivermectin, looked at the impact on internal helminthes and parasitic skin diseases. The researchers concluded that “mass treatment with ivermectin was an effective and safe means of reducing the prevalence of most of the parasitic diseases prevalent in a poor community in North-East Brazil. The effects of treatment lasted for a prolonged period of time”. This study also represented the first published report of human medical intervention using ivermectin that had not been produced by the hitherto traditional manufacturer, Merck & Co. Inc., the patent on the drug expiring in 1997.66)
In reality, the renewed interest in fighting tropical diseases, including the involvement of the pharmaceutical industry, which has become increasingly evident over the past three decades, and which has saved lives and improved the welfare of billions of people, notably the poor and disadvantaged in the topics, can be traced back to the 1987 introduction of ivermectin for use in humans. According to a recent report, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) data show that the global pharmaceutical industry provided over $9.2 billion in health interventions (medicines and equipment) between 2000–2007 alone, benefitting 1.75 billion people worldwide.67) The hitherto unprecedented donation of ivermectin in 1987 can rightly be seen to be the origin of this philanthropic outpouring.
Since the inception of the Mectizan Donation Programme, Merck has donated well over 2.5 billion Mectizan® tablets for Onchocerciasis treatment, with in excess of 700 million treatments authorised. Currently, some 80–90 million people are taking the drug annually through MDA in Africa, Latin America and Yemen. A further 300 million total treatments have been approved for lymphatic filariasis, with around 90 million treatments being administered annually (Fig. (Fig.8 ).8 ). At present 33 countries are receiving ivermectin for Onchocerciasis and 15 for Lymphatic filariasis. Consequently, around US$4 billion worth of ivermectin tablets have been donated to date. In 2010, Ecuador became the second country in the Americas to halt River Blindness transmission. It is hoped that transmission of the disease in the Western hemisphere will be stopped by 2012—a goal that will have been achieved thanks to twice-yearly MDA with ivermectin. Lymphatic filariasis is targeted for global elimination by 2020, and, if all goes well, Onchocerciasis may well be eliminated from Africa soon thereafter.
[IMG alt="An external file that holds a picture, illustration, etc.
Object name is pjab-87-013-g008.jpg"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/bin/pjab-87-013-g008.jpg[/IMG]
Open in a separate window
Figure 8.
Trend in ivermectin treatments approved (1988–2008).
It has, thus far, been a long and eventful journey from ivermectin’s origins in Japanese soil. Fortunately, and contrary to the position seen with most antibiotics, despite several decades of monotherapy and occasional suboptimal responses observed in some individuals, there is no conclusive evidence that drug resistance is developing in human Onchocercal parasites. Not surprisingly, public health specialists worldwide are now calling for greater and more extensive use of ivermectin,68) labelling MDA of the ‘wonder drug’ quite simply as “an underutilized public health strategy”. In response, the Kitasato Institute has initiated a global collaboration to investigate all properties and potential of a range of ivermectin analogues, both individually and in combination, particularly with a view to having a ready-made alternative should resistance to current ivermectin monotherapy ever threaten ongoing disease elimination campaigns.
www.ncbi.nlm.nih.gov
BYE
BYE
BYE
BUT
THE BANKRUPTCY OF BIG PHARMA
Ivermectin, 'wonder drug' from Japan: the human use perspective
New horizons
Ivermectin has continually proved to be astonishingly safe for human use. Indeed, it is such a safe drug, with minimal side effects, that it can be administered by non-medical staff and even illiterate individuals in remote rural communities, provided that they have had some very basic, appropriate training. This fact has helped contribute to the unsurpassed beneficial impact that the drug has had on human health and welfare around the globe, especially with regard to the campaign to fight Onchocerciasis.57)
Today, ivermectin is being increasingly used worldwide to combat other diseases in humans, such as Strongyloidiasis (which infects some 35 million each year), scabies (which causes 300 million cases annually), Pediculosis, Gnathostomiasis and Myiasis—and new and promising properties and uses for ivermectin and other avermectin derivatives are continuing to be found.58) These include activity against another neglected tropical disease, Leishmaniasis.59,60) Of perhaps even greater significance is the evidence that the use of ivermectin has both direct and indirect beneficial impact on improving community health. Studies of long-term treatment with ivermectin to control Onchocerciasis have shown that use of the drug is additionally associated with significant reduction in the prevalence of infection with any soil-transmitted helminth parasites (including Ascaris, Trichuris and hookworm), most or all of which are deemed to be major causes of the morbidity arising from poor childhood nutrition and growth.61) It is also known that the prevalence of head lice is markedly reduced in children taking ivermectin tablets62) and that scabies is markedly reduced in populations taking the drug regularly.63) Above all, ivermectin has proved to be a medicine of choice for the world’s rural poor. In many underprivileged communities throughout the tropics, intestinal worms and parasitic skin diseases are extremely common and associated with significant morbidity. They usually co-exist, with many individuals infected with both ecto- and endoparasites.64,65) Mass treatment of poly-parasitized populations is deemed to be the best means of control and ivermectin is the ideal drug for such interventions. A recent study in Brazil, using locally produced ivermectin, looked at the impact on internal helminthes and parasitic skin diseases. The researchers concluded that “mass treatment with ivermectin was an effective and safe means of reducing the prevalence of most of the parasitic diseases prevalent in a poor community in North-East Brazil. The effects of treatment lasted for a prolonged period of time”. This study also represented the first published report of human medical intervention using ivermectin that had not been produced by the hitherto traditional manufacturer, Merck & Co. Inc., the patent on the drug expiring in 1997.66)
In reality, the renewed interest in fighting tropical diseases, including the involvement of the pharmaceutical industry, which has become increasingly evident over the past three decades, and which has saved lives and improved the welfare of billions of people, notably the poor and disadvantaged in the topics, can be traced back to the 1987 introduction of ivermectin for use in humans. According to a recent report, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) data show that the global pharmaceutical industry provided over $9.2 billion in health interventions (medicines and equipment) between 2000–2007 alone, benefitting 1.75 billion people worldwide.67) The hitherto unprecedented donation of ivermectin in 1987 can rightly be seen to be the origin of this philanthropic outpouring.
Since the inception of the Mectizan Donation Programme, Merck has donated well over 2.5 billion Mectizan® tablets for Onchocerciasis treatment, with in excess of 700 million treatments authorised. Currently, some 80–90 million people are taking the drug annually through MDA in Africa, Latin America and Yemen. A further 300 million total treatments have been approved for lymphatic filariasis, with around 90 million treatments being administered annually (Fig. (Fig.8 ).8 ). At present 33 countries are receiving ivermectin for Onchocerciasis and 15 for Lymphatic filariasis. Consequently, around US$4 billion worth of ivermectin tablets have been donated to date. In 2010, Ecuador became the second country in the Americas to halt River Blindness transmission. It is hoped that transmission of the disease in the Western hemisphere will be stopped by 2012—a goal that will have been achieved thanks to twice-yearly MDA with ivermectin. Lymphatic filariasis is targeted for global elimination by 2020, and, if all goes well, Onchocerciasis may well be eliminated from Africa soon thereafter.
[IMG alt="An external file that holds a picture, illustration, etc.
Object name is pjab-87-013-g008.jpg"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/bin/pjab-87-013-g008.jpg[/IMG]
Open in a separate window
Figure 8.
Trend in ivermectin treatments approved (1988–2008).
It has, thus far, been a long and eventful journey from ivermectin’s origins in Japanese soil. Fortunately, and contrary to the position seen with most antibiotics, despite several decades of monotherapy and occasional suboptimal responses observed in some individuals, there is no conclusive evidence that drug resistance is developing in human Onchocercal parasites. Not surprisingly, public health specialists worldwide are now calling for greater and more extensive use of ivermectin,68) labelling MDA of the ‘wonder drug’ quite simply as “an underutilized public health strategy”. In response, the Kitasato Institute has initiated a global collaboration to investigate all properties and potential of a range of ivermectin analogues, both individually and in combination, particularly with a view to having a ready-made alternative should resistance to current ivermectin monotherapy ever threaten ongoing disease elimination campaigns.
Ivermectin, ‘Wonder drug’ from Japan: the human use perspective - PMC
Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin—originating solely from a single microorganism isolated at the Kitasato Intitute, Tokyo, Japan from Japanese soil—has had an immeasurably beneficial ...
www.ncbi.nlm.nih.gov
BYE
BYE
BYE
Comoduca
co-founder
in questo caso ( enel energia ) di quanto è l'aumento ?
da un minimo del 883, 75 % ad un massimo del 1653.59%
controllate la vs fornitura, qui si rischia di farsi male anche con il solo consumo standard dei 3KWh
Comoduca
co-founder
chi produce ?
